5TH JOINT TRIENNIAL CONGRESS OF THE EUROPEAN AND AMERICAS COMMITTEES FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

19 – 22 OCTOBER 2011
AMSTERDAM, THE NETHERLANDS

www.ectrims.eu/2011

PRELIMINARY PROGRAMME
Committees

ECTRIMS Executive Committee
M. Clanet, President
F. Fazekas
R. Gold
D. Miller
X. Montalban, Secretary
P. Soelberg Sørensen, Treasurer
M. Trojano, Vice President

ECTRIMS Board of Directors
J. Cohen
S. Dhib-Jalbut, Secretary/Treasurer
M. Freedman
K. Johnson, Past President
P. O’Connor, President Elect
E. Waubant
J. Wolinsky, President

ACTRIMS Board of Directors
C. Polman, Chair
B. Uitdehaag
E. de Vries

Local Organising Committee
F. Barkhof
E. Boddeke
C. Dijkstra
J. Geurts
R. Hintzen
C. Polman, Chair
C. Teunissen
B. Uitdehaag
P. van der Valk
H. Vrenken

Scientific Committee
J. Antel
F. Barkhof
D. Callegaro
M. Clanet
J. Cohen
M. Freedman
R. Gold
L. Kappos
X. Montalban
C. Polman
P. Soelberg Sørensen
M. Trojano, Chair
B. Uitdehaag
E. Waubant
J. Wolinsky

Toulouse, FR
Graz, AT
Bochum, DE
London, UK
Barcelona, ES
Copenhagen, DK
Bari, IT
Cleveland, US
New Brunswick, US
Ottawa, CA
Baltimore, US
Toronto, CA
San Francisco, US
Houston, US
Amsterdam
Groningen
Amsterdam
Amsterdam
Rotterdam
Amsterdam
Amsterdam
Amsterdam
Amsterdam
Amsterdam
Montreal, CA
Amsterdam, NL
Sao Paulo, BR
Toulouse, FR
Cleveland, US
Ottawa, CA
Bochum, DE
Basel, CH
Barcelona, ES
Amsterdam, NL
Copenhagen, DK
Bari, IT
Amsterdam, NL
San Francisco, US
Houston, US

Table of Contents

Committees .................................................. 3
Acknowledgements ........................................ 3
Important Addresses ....................................... 4
Important Dates ........................................... 4
Welcome Address ........................................ 5
Programme Overview ................................. 6 – 9
Invited Speakers and Chairs ........................ 10
Scientific Programme ................................. 11 – 18
Call for Abstracts ........................................ 19 – 21
Social Events ............................................. 22 – 23
Tours ...................................................... 24 – 26
Registration ................................................ 27 – 28
Hotel Accommodation ................................. 28 – 29
General Information .................................... 30 – 32
Travelling to the Amsterdam RAI Exhibition ....... 33
Plan and Location of the Amsterdam RAI Exhibition ... 34
The Amsterdam RAI Exhibition ..................... 35
Amsterdam City Map and Hotels .................... 36 – 37

Acknowledgements

The Organising Committee expresses its thanks and appreciation to all those who are generously contributing to the success of the ECTRIMS / ACTRIMS 2011.

Allergan
Almirall S.A.
Bayer Schering Pharma AG
Biogen Idec
European Charcot Foundation
Genzyme
Merck Serono S.A.
Novartis Pharma AG
Sanofi-aventis
Teva Pharmaceutical Industries

Source Photographs: Amsterdam Tourism & Congress Board
## Important Addresses

### Scientific Secretariat
Prof. Chris Polman  
VUmc MS Center Amsterdam  
VUmc, room PK 4X 180  
P.O. Box 7057  
1007 MB Amsterdam / The Netherlands  
Phone  +31 20 4449 088  
Fax  +31 20 4443 670  
E-mail  ectrims2011@vumc.nl

### Administrative Secretariat
ECTRIMS / ACTRIMS 2011  
c/o Congrex Switzerland Ltd.  
Peter Merian-Strasse 80  
P.O. Box  
4002 Basel / Switzerland  
Phone  +41 61 686 77 11  
Fax  +41 61 686 77 88  
E-mail  ectrims@congrex.com  
www.ectrims.eu/2011

### Local Agency
Congrex Holland BV  
Janneke van Kempen  
P.O. Box 302  
1000 AH Amsterdam / The Netherlands  
Phone  +31 20 5040 232  
Fax  +31 20 5040 211  
E-mail  ectrims.local@congrex.com

### Official Airline
Air France and KLM are pleased to be appointed as  
the Official Airlines for the ECTRIMS / ACTRIMS 2011  
(see page 29 for benefits and booking details).

### Official Agent for Accommodation and Travel

#### Hotel Accommodation
Congrex Travel Ltd.  
Peter Merian-Strasse 80  
P.O. Box  
4002 Basel / Switzerland  
Phone  +41 61 690 94 11  
Fax  +41 61 690 94 14  
E-mail  ectrims.hotel@congrex.com

#### Flight Bookings
Congrex Travel Ltd.  
Peter Merian-Strasse 80  
P.O. Box  
4002 Basel / Switzerland  
Phone  +41 61 560 75 60  
Fax  +41 61 690 92 14  
E-mail  ectrims.flights@congrex.com

### Important Dates

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 May 2011</td>
<td>Deadline for submission of abstracts</td>
</tr>
<tr>
<td>Mid July 2011</td>
<td>Notification of abstract authors</td>
</tr>
<tr>
<td>2 August 2011</td>
<td>Deadline for submission of late breaking abstracts</td>
</tr>
<tr>
<td>24 August 2011</td>
<td>Deadline for early registration fee</td>
</tr>
<tr>
<td>October 2011</td>
<td>Publication of Final Programme</td>
</tr>
<tr>
<td>19–22 October 2011</td>
<td>5th Joint Triennial Congress of ECTRIMS and ACTRIMS</td>
</tr>
</tbody>
</table>

Welcome Address

Dear Colleagues and Friends,

On behalf of ECTRIMS, ACTRIMS and the Local Organizing Committee it is our pleasure to invite you to the 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), which will be held in Amsterdam, the Netherlands, 19–22 October 2011.

These are exciting times for MS research, with diagnosis becoming more accurate, disease mechanisms more and more unraveled, and several new treatment options available. These exciting developments also pose new challenges. How can we personalize treatment? How can the risks of treatment be minimized? Do we understand neurodegeneration, and can we prevent or treat it? Leading international experts will present and discuss their newest insights on these and other topics.

This joint congress will bring together thousands of scientists and clinicians from all over the world, all committed to understanding and better managing MS and related diseases. Integration of basic and clinical studies is crucial to understand disease mechanisms and to provide the answers to important questions, for example those related to neurodegeneration, one of the major unresolved problems in MS. During the next months the Scientific Program Committee will prepare a program which covers important basic and clinical concepts, new developments (and controversies) in MS diagnosis and treatment, as well as “hot topics” focusing on emerging ideas.

Amsterdam is a natural choice for this Joint Triennial ECTRIMS / ACTRIMS Congress. Its name is derived from Amsteller-dam, indicative of the city’s origin: a dam in the river Amstel. Settled as a small fishing village in the late 12th century, Amsterdam became one of the most important ports in the world during the 17th century, the Dutch Golden Age, a result of its innovative developments in trade. Since, it has been a leading trading and cultural city, where art, commerce, creativity and tolerance are guiding principles. Nowadays, Amsterdam’s main attractions include the historic canals, the Rijksmuseum, van Gogh Museum, Stedelijk Museum, Hermitage Amsterdam, Anne Frank House, the restored facades of historic buildings representing all periods in its history, as well as the many markets and coffee shops.

Amsterdam is easily accessible by its direct worldwide air links to all major regions of the world, and it has a wide range of hotel accommodations in all categories. The venue of the congress, the newly renovated Amsterdam RAI Exhibition & Convention Centre, is one of the busiest exhibition and conference centers in the world, with easy connections to both the international airport and main train stations.

We are looking forward to meeting you in Amsterdam, in October 2011, to a congress that will offer exciting science, an enjoyable atmosphere, and many opportunities to meet with colleagues.

C. Polman
Chair ECTRIMS 2011

M. Clenet
ECTRIMS President

J. Wolinsky
ACTRIMS President

X. Montalban
ECTRIMS Secretary
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30–10.00</td>
<td>Teaching Course 1: Meet the professors; a case-based approach to diagnosis and treatment</td>
</tr>
<tr>
<td>08.30–10.00</td>
<td>Teaching Course 2: Symptom management in MS</td>
</tr>
<tr>
<td>08.30–10.00</td>
<td>Teaching Course 3: Biomarkers in CSF</td>
</tr>
<tr>
<td>08.30–10.00</td>
<td>Teaching Course 4: MRI in clinical setting</td>
</tr>
<tr>
<td>08.30–10.00</td>
<td>Teaching Course 5: Neuroinflammation, neurodegeneration, and tissue repair – how are they related?</td>
</tr>
<tr>
<td>08.30–10.00</td>
<td>Teaching Course 6: Gene-environment interactions in MS</td>
</tr>
<tr>
<td>10.00–10.30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10.30–12.00</td>
<td>Teaching Course 7: Stem cell therapy – translating experimental data into MS therapy</td>
</tr>
<tr>
<td>10.30–12.00</td>
<td>Teaching Course 8: Disease-modifying therapy in MS – current and emerging treatment</td>
</tr>
<tr>
<td>10.30–12.00</td>
<td>Teaching Course 9: New technologies in neuroimmunology</td>
</tr>
<tr>
<td>10.30–12.00</td>
<td>Teaching Course 10: Advanced MR techniques</td>
</tr>
<tr>
<td>10.30–12.00</td>
<td>Teaching Course 11: Neuroinflammation and tissue repair – what can we learn from animal models?</td>
</tr>
<tr>
<td>10.30–12.00</td>
<td>Teaching Course 12: From genes to function</td>
</tr>
<tr>
<td>12.00 – 12.30</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12.30–14.00</td>
<td>Satellite Symposium: European Charcot Foundation</td>
</tr>
<tr>
<td>14.00–15.30</td>
<td>Young Scientific Investigators’ Session I</td>
</tr>
<tr>
<td>15.30–16.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16.00–17.15</td>
<td>Young Scientific Investigators’ Session II</td>
</tr>
<tr>
<td>17.15–18.15</td>
<td>Satellite Symposium: Teva</td>
</tr>
<tr>
<td>18.30–19.30</td>
<td>Satellite Symposium: Sanofi-aventis</td>
</tr>
<tr>
<td>20.00</td>
<td>Welcome Reception at the National Maritime Museum Amsterdam</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>08.30</td>
<td>Plenary Session 1</td>
</tr>
<tr>
<td>09.00</td>
<td>Parallel Session 1: How to decide whether a patient responds to treatment</td>
</tr>
<tr>
<td>10.00</td>
<td>Parallel Session 2: Cellular infiltration into the brain: new ways for immunomodulation in MS</td>
</tr>
<tr>
<td>11.00</td>
<td>Parallel Session 3: OCT in MS</td>
</tr>
<tr>
<td>12.00</td>
<td>Lunch Break &amp; Poster Viewing</td>
</tr>
<tr>
<td>12.45</td>
<td>Satellite Symposium: Biogen Idec</td>
</tr>
<tr>
<td>14.00</td>
<td>Parallel Session 4: Functional reorganisation and rehabilitation</td>
</tr>
<tr>
<td>14.00</td>
<td>Parallel Session 5: New biomarkers for MS</td>
</tr>
<tr>
<td>14.00</td>
<td>Parallel Session 6: Paediatric MS</td>
</tr>
<tr>
<td>17.00</td>
<td>Hot Topics in MS 1: Diagnostic criteria for MS</td>
</tr>
<tr>
<td>17.00</td>
<td>Hot Topics in MS 2: Mitochondria in MS</td>
</tr>
<tr>
<td>17.00</td>
<td>Hot Topics in MS 3: High field MRI in MS</td>
</tr>
<tr>
<td>18.00</td>
<td>Satellite Symposium: Merck Serono S.A.</td>
</tr>
<tr>
<td>18.15</td>
<td>Satellite Symposium: Bayer Schering Pharma AG</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>08.00</td>
<td>ECTRIMS Council Meeting (by invitation only)</td>
</tr>
</tbody>
</table>
| 08.00-09.00 | Satellite Symposium  
Allergan                                    |
| 09.15-10.15 | Platform presentation of selected abstracts I                      |
| 10.00    | Parallel Session 7  
Grey matter damage in MS                                      |
| 10.15-10.45 | Coffee Break & Poster Viewing                                   |
| 10.45-12.15 | Parallel Session 8  
The importance of B-cells in MS                               |
| 10.45-12.15 | Parallel Session 9  
How to measure clinical progression                              |
| 10.45-12.15 | Parallel Session 9  
How to measure clinical progression                              |
| 12.15-12.45 | Lunch Break & Poster Viewing                                      |
| 12.45-13.45 | Satellite Symposium  
Novartis Pharma AG                                    |
| 14.00-15.00 | Parallel Session 10  
Cognitive decline in MS                                   |
| 14.00-15.30 | Parallel Session 11  
Cell based therapy in MS                                |
| 14.00-15.30 | Parallel Session 12  
New developments in the epidemiology of MS                   |
| 15.30-17.00 | Poster Viewing Session                                               |
| 17.00-17.45 | Hot Topics in MS 4  
CCSVI                                                  |
| 17.00-17.45 | Hot Topics in MS 5  
MS: neurodegeneration                                          |
| 17.00-17.45 | Hot Topics in MS 6  
Risk management for disease-modifying treatments in MS    |
| 18.00    | Satellite Symposium  
Almirall                                                  |
| 19.15-20.15 | Satellite Symposium  
Genzyme                                               |
| 20.30    | Official Conference Dinner at the Beurs van Berlage                |
Programme Overview

Saturday, 22 October 2011

08.30
09.00
09.30
10.00
10.30
11.00
11.30
12.00
12.30
13.00
13.30

08.30–09.30
Parallel Session 13
Late Breaking News

09.30–10.15
Charcot Lecture

10.15–10.45
Coffee Break & Poster Viewing

10.45–11.30
ACTRIMS Donald Paty Memorial Lecture

11.30–13.00
Plenary Session 2
ECTRIMS / ACTRIMS highlights
Awards

13.00–13.30
Lunch

End of Meeting

Advance Notice ECTRIMS 2012

28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

10–13 October 2012, Lyon, France

www.ectrims.eu
### Invited Speakers and Chairs

<table>
<thead>
<tr>
<th>Name</th>
<th>First Name</th>
<th>Name</th>
<th>First Name</th>
<th>Name</th>
<th>First Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aloisi</td>
<td>Francesca</td>
<td>Hartung</td>
<td>Hans-Peter</td>
<td>Hartung</td>
<td>Hans-Peter</td>
</tr>
<tr>
<td>Amato</td>
<td>Maria</td>
<td>Hemmer</td>
<td>Bernhard</td>
<td>Hemmer</td>
<td>Bernhard</td>
</tr>
<tr>
<td>Antel</td>
<td>Jack</td>
<td>Hillert</td>
<td>Jan</td>
<td>Hillert</td>
<td>Jan</td>
</tr>
<tr>
<td>Ascherio</td>
<td>Alberto</td>
<td>Hintzen</td>
<td>Rogier</td>
<td>Hintzen</td>
<td>Rogier</td>
</tr>
<tr>
<td>Balcer</td>
<td>Laura</td>
<td>Hohlfeld</td>
<td>Reinhard</td>
<td>Hohlfeld</td>
<td>Reinhard</td>
</tr>
<tr>
<td>Banwell</td>
<td>Brenda</td>
<td>Hutchinson</td>
<td>Michael</td>
<td>Hutchinson</td>
<td>Michael</td>
</tr>
<tr>
<td>Baranzini</td>
<td>Sergio</td>
<td>Kappos</td>
<td>Ludwig</td>
<td>Kappos</td>
<td>Ludwig</td>
</tr>
<tr>
<td>Barkhof</td>
<td>Frederik</td>
<td>Keirstead</td>
<td>Hans</td>
<td>Keirstead</td>
<td>Hans</td>
</tr>
<tr>
<td>Bar-Or</td>
<td>Amit</td>
<td>Kesselring</td>
<td>Jürg</td>
<td>Kesselring</td>
<td>Jürg</td>
</tr>
<tr>
<td>Bates</td>
<td>David</td>
<td>Khan</td>
<td>Omar</td>
<td>Khan</td>
<td>Omar</td>
</tr>
<tr>
<td>Benedict</td>
<td>Ralph</td>
<td>Killestein</td>
<td>Joep</td>
<td>Killestein</td>
<td>Joep</td>
</tr>
<tr>
<td>Boddeke</td>
<td>Eric</td>
<td>Lassmann</td>
<td>Hans</td>
<td>Lassmann</td>
<td>Hans</td>
</tr>
<tr>
<td>Bourdette</td>
<td>Dennis</td>
<td>Llibau</td>
<td>Roland</td>
<td>Llibau</td>
<td>Roland</td>
</tr>
<tr>
<td>Brück</td>
<td>Wolfgang</td>
<td>Lubetzki</td>
<td>Catherine</td>
<td>Lubetzki</td>
<td>Catherine</td>
</tr>
<tr>
<td>Calabresi</td>
<td>Peter</td>
<td>Lublin</td>
<td>Fred</td>
<td>Lublin</td>
<td>Fred</td>
</tr>
<tr>
<td>Caiazzo</td>
<td>Laura</td>
<td>Lucchini</td>
<td>Claudia</td>
<td>Lucchini</td>
<td>Claudia</td>
</tr>
<tr>
<td>Chiaravalloti</td>
<td>Nancy</td>
<td>Lycke</td>
<td>Jan</td>
<td>Lycke</td>
<td>Jan</td>
</tr>
<tr>
<td>Ciccarelli</td>
<td>Olga</td>
<td>Marie</td>
<td>Ruth</td>
<td>Marie</td>
<td>Ruth</td>
</tr>
<tr>
<td>Clanet</td>
<td>Michel</td>
<td>Martino</td>
<td>Gianvito</td>
<td>Martino</td>
<td>Gianvito</td>
</tr>
<tr>
<td>Cohen</td>
<td>Jeffrey</td>
<td>Matthews</td>
<td>Paul</td>
<td>Jeffrey</td>
<td>Paul</td>
</tr>
<tr>
<td>Comabella</td>
<td>Manuel</td>
<td>McFarland</td>
<td>Henry</td>
<td>Manuel</td>
<td>Henry</td>
</tr>
<tr>
<td>Comi</td>
<td>Giancarlo</td>
<td>Miller</td>
<td>Aaron</td>
<td>Giancarlo</td>
<td>Aaron</td>
</tr>
<tr>
<td>Cook</td>
<td>Stuart</td>
<td>Montalban</td>
<td>Xavier</td>
<td>Stuart</td>
<td>Xavier</td>
</tr>
<tr>
<td>Correale</td>
<td>Jorge</td>
<td>Munger</td>
<td>Kassandra</td>
<td>Jorge</td>
<td>Kassandra</td>
</tr>
<tr>
<td>D’E Stefano</td>
<td>Nicola</td>
<td>O’Connor</td>
<td>Paul</td>
<td>Nicola</td>
<td>Paul</td>
</tr>
<tr>
<td>De Vries</td>
<td>Hilly</td>
<td>Olsson</td>
<td>Tomas</td>
<td>Hilly</td>
<td>Tomas</td>
</tr>
<tr>
<td>Derfuss</td>
<td>Tobias</td>
<td>Palace</td>
<td>Jacqueline</td>
<td>Tobias</td>
<td>Jacqueline</td>
</tr>
<tr>
<td>Dijkstra</td>
<td>Christine</td>
<td>Pelletier</td>
<td>Daniel</td>
<td>Christine</td>
<td>Daniel</td>
</tr>
<tr>
<td>Doeppe</td>
<td>Florian</td>
<td>Perry</td>
<td>Hugh</td>
<td>Florian</td>
<td>Hugh</td>
</tr>
<tr>
<td>Doussset</td>
<td>Vincent</td>
<td>Petzold</td>
<td>Axel</td>
<td>Vincent</td>
<td>Axel</td>
</tr>
<tr>
<td>Ebers</td>
<td>George</td>
<td>Plant</td>
<td>Gordon</td>
<td>George</td>
<td>Gordon</td>
</tr>
<tr>
<td>Edan</td>
<td>Gilles</td>
<td>Polman</td>
<td>Chris</td>
<td>Gilles</td>
<td>Chris</td>
</tr>
<tr>
<td>Fazekas</td>
<td>Frank</td>
<td>Prat</td>
<td>Alexandre</td>
<td>Frank</td>
<td>Alexandre</td>
</tr>
<tr>
<td>Filippi</td>
<td>Massimo</td>
<td>Rocca</td>
<td>Mara</td>
<td>Massimo</td>
<td>Mara</td>
</tr>
<tr>
<td>Freedman</td>
<td>Mark</td>
<td>Rudick</td>
<td>Richard</td>
<td>Mark</td>
<td>Richard</td>
</tr>
<tr>
<td>Fugger</td>
<td>Lars</td>
<td></td>
<td></td>
<td>Lars</td>
<td></td>
</tr>
<tr>
<td>Gaurts</td>
<td>Jeroen</td>
<td></td>
<td></td>
<td>Jeroen</td>
<td></td>
</tr>
<tr>
<td>Giovannoni</td>
<td>Gavin</td>
<td></td>
<td></td>
<td>Gavin</td>
<td></td>
</tr>
<tr>
<td>Gold</td>
<td>Ralf</td>
<td></td>
<td></td>
<td>Ralf</td>
<td></td>
</tr>
<tr>
<td>Goodman</td>
<td>Andrew</td>
<td></td>
<td></td>
<td>Andrew</td>
<td></td>
</tr>
<tr>
<td>Green</td>
<td>Ari</td>
<td></td>
<td></td>
<td>Ari</td>
<td></td>
</tr>
<tr>
<td>Schmidt</td>
<td>Klaus</td>
<td></td>
<td></td>
<td>Klaus</td>
<td></td>
</tr>
<tr>
<td>Scolding</td>
<td>Neil</td>
<td></td>
<td></td>
<td>Scolding</td>
<td>Neil</td>
</tr>
<tr>
<td>Seelbjerger</td>
<td>Per</td>
<td></td>
<td></td>
<td>Seelbjerger</td>
<td>Per</td>
</tr>
<tr>
<td>Sorensen</td>
<td>Maria</td>
<td></td>
<td></td>
<td>Sorensen</td>
<td>Maria</td>
</tr>
<tr>
<td>Sormani</td>
<td>Christine</td>
<td></td>
<td></td>
<td>Sormani</td>
<td>Christine</td>
</tr>
<tr>
<td>Stadelmann</td>
<td>Larry</td>
<td></td>
<td></td>
<td>Stadelmann</td>
<td>Larry</td>
</tr>
<tr>
<td>Steinman</td>
<td></td>
<td></td>
<td></td>
<td>Steinman</td>
<td></td>
</tr>
<tr>
<td>Tenenbaum</td>
<td>Silvia</td>
<td></td>
<td></td>
<td>Tenenbaum</td>
<td>Silvia</td>
</tr>
<tr>
<td>Teunissen</td>
<td>Charlotte</td>
<td></td>
<td></td>
<td>Teunissen</td>
<td>Charlotte</td>
</tr>
<tr>
<td>Thompson</td>
<td>Alan</td>
<td></td>
<td></td>
<td>Thompson</td>
<td>Alan</td>
</tr>
<tr>
<td>Tintore</td>
<td>Bruce</td>
<td></td>
<td></td>
<td>Tintore</td>
<td>Bruce</td>
</tr>
<tr>
<td>Trapp</td>
<td>Helen</td>
<td></td>
<td></td>
<td>Trapp</td>
<td>Helen</td>
</tr>
<tr>
<td>Tremlett</td>
<td>Maria</td>
<td></td>
<td></td>
<td>Tremlett</td>
<td>Maria</td>
</tr>
<tr>
<td>Trojano</td>
<td></td>
<td></td>
<td></td>
<td>Trojano</td>
<td></td>
</tr>
<tr>
<td>Utdehaag</td>
<td>Bernard</td>
<td></td>
<td></td>
<td>Utdehaag</td>
<td>Bernard</td>
</tr>
<tr>
<td>Van der Valk</td>
<td>Paul</td>
<td></td>
<td></td>
<td>Van der Valk</td>
<td>Paul</td>
</tr>
<tr>
<td>van Oosten</td>
<td>Bob</td>
<td></td>
<td></td>
<td>van Oosten</td>
<td>Bob</td>
</tr>
<tr>
<td>Vrenken</td>
<td>Hugo</td>
<td></td>
<td></td>
<td>Vrenken</td>
<td>Hugo</td>
</tr>
<tr>
<td>Vukusic</td>
<td>Sandra</td>
<td></td>
<td></td>
<td>Vukusic</td>
<td>Sandra</td>
</tr>
<tr>
<td>Wattjes</td>
<td>Mike</td>
<td></td>
<td></td>
<td>Wattjes</td>
<td>Mike</td>
</tr>
<tr>
<td>Waubant</td>
<td>Emmanuelle</td>
<td></td>
<td></td>
<td>Waubant</td>
<td>Emmanuelle</td>
</tr>
<tr>
<td>Weiner</td>
<td>Howard</td>
<td></td>
<td></td>
<td>Weiner</td>
<td>Howard</td>
</tr>
<tr>
<td>Wiendl</td>
<td>Heinz</td>
<td></td>
<td></td>
<td>Wiendl</td>
<td>Heinz</td>
</tr>
<tr>
<td>Wolinsky</td>
<td>Jerry</td>
<td></td>
<td></td>
<td>Wolinsky</td>
<td>Jerry</td>
</tr>
<tr>
<td>Zipp</td>
<td>Frauke</td>
<td></td>
<td></td>
<td>Zipp</td>
<td>Frauke</td>
</tr>
</tbody>
</table>
Teaching Courses

08.30 – 10.00  Teaching Course 1
Meet the professors: a case based approach to diagnosis and treatment
Chairs: D. Bates (Newcastle-upon-Tyne, UK)
A. Miller (New York, US)

In this programme, two experienced MS clinicians, from either side of the Atlantic Ocean, will engage the audience in an interactive programme that reviews several clinically important issues regarding the diagnosis and management of MS and related demyelinating disorders. Recently revised diagnostic criteria will be discussed, as well as the use of an increasing number of disease modifying therapies. Strategies for drug selection that incorporate risk-benefit analysis will be considered.

08.30 – 10.00  Teaching Course 2
Symptom management in MS
Chairs: A. Goodman (Rochester, US)
A. Thompson (London, UK)

People with multiple sclerosis (MS) experience a wide variety of neurological symptoms. Over time, worsening of such symptoms increasingly compromises independence, economic productivity, and the ability to perform activities of daily living. The physical, psychological, social, and financial impact can be devastating for people with MS and their families. Although important advances with disease modifying therapies now diminish the likelihood of developing new lesions, in general, these do not benefit already existing symptoms. Mobility impairment is among the commonest and most disabling MS symptoms. Treatment of such symptoms remains an essential cornerstone of comprehensive care of patients with MS, and arguably, enhances quality of life as much as the disease-modifying medications. This course will update research findings and review strategies for management of mobility problems in patients with MS.

08.30 – 10.00  Teaching Course 3
Biomarkers in CSF
Chairs: B. Hemmer (Munich, DE)
C. Teunissen (Amsterdam, NL)

There is a strong interest in CSF biomarkers for multiple sclerosis, as these may serve as objective, relatively cheap, and dynamic aids in the diagnosis, prognosis and monitoring of disease progression in MS. CSF biomarker evaluation needs specific expertise and infrastructure. The BioMS-eu network provides a strong framework to gain this expertise, and a teaching course at ECTRIMS is the ideal platform to share and discuss this knowledge with any person with interest in CSF biomarker evaluation.

08.30 – 10.00  Teaching Course 4
MRI in clinical setting
Chairs: N. De Stefano (Siena, IT)
J. Palace (Oxford, UK)

MRI plays a crucial role in the diagnosis of MS. The faculty of MAGNIMS and North-American experts will review the typical MRI features of the MS brain and spinal cord, will provide an update on the MRI diagnostic criteria for MS and will emphasize the clinical use of MRI indices for monitoring disease progression, treatment efficacy and safety in the individual patient. The importance of neurodegeneration from the earliest stages of the disease will also be discussed. Upon completion, participants will have updated knowledge of the usage of MRI in the clinical setting, for individual MS patient management.

08.30 – 10.00  Teaching Course 5
Neuroinflammation, neurodegeneration, and tissue repair – how are they related?
Chairs: W. Brück (Göttingen, DE)
C. Lucchinetti (Rochester, US)

The present teaching course will focus on the relationship between inflammation, neurodegeneration and repair in multiple sclerosis (MS). Nicole Schaeren-Wiemers will focus on molecular changes in the normal appearing white and grey matter of MS brains. Here, early molecular changes occur that may help identifying possible pathogenetic mechanisms of lesion development. The grey matter is substantially involved in the pathology of MS and reveals extensive demyelination, possibly from early disease on. Claudia Lucchinetti will in detail describe the quantity and quality of inflammation in cortical MS lesions and their role in the development of grey matter demyelination. Hans Lassmann will focus on the correlation between inflammation and neurodegeneration, especially axonal damage, in chronic MS lesions. He will clarify whether neurodegeneration is independent or dependent on inflammation within the lesions. Repair, especially remyelination, is limited in the MS brain. Wolfgang Brück will describe the extent of spontaneous remyelination in different disease stages and discuss the cause of remyelination failure in MS.
08.30 – 10.00  Teaching Course 6
Gene-environment interactions in MS
Chairs: A. Aschiero (Boston, US)
G. Ebers (Oxford, UK)

This course will introduce the concept of interaction from an epidemiological perspective and provide an updated review of gene-environment interactions in MS. Specific topics will include: the definition of interaction in biostatistics/epidemiology and its relation to biology; the importance of investigating gene-environment interactions in MS; the role of vitamin D and EBV infection as risk factors for MS; and potential interactions between vitamin D or EBV and the HLA-DR15 MS risk allele as well as other genetic polymorphisms.

10.00 – 10.30  Coffee Break

10.30 – 12.00  Teaching Course 7
Stem cell therapy – translating experimental data into MS therapy
Chairs: M. Freedman (Ottawa, CA)
G. Martino (Milan, IT)

In this course we will focus on somatic stem cell types whose therapeutic potential has been variably and reliably explored in pre-clinical model of multiple sclerosis (MS) or in patients with MS. These stem cells are haematopoietic stem cells, mesenchymal stem cells, and neural stem cells. Owing to the fact that regeneration of long tract axons and replacement of neurons by stem cell therapy has not been achieved so far neither in experimental nor in human MS, we will focus on the extent to which transplanted stem cells contribute either to immunomodulation or remyelination. As a consequence, stem cell-based therapies for MS patients should be regarded so far as an alternative tool to prevent damage and/or foster remyelination.

10.30 – 12.00  Teaching Course 8
Disease-modifying therapy in MS – current and emerging treatment
Chairs: S. Cook (Newark, US)
R. Gold (Bochum, DE)

This ECTRIMS teaching course ‘Disease-modifying therapy in MS – current and emerging treatment’ will give the audience an overview of established DMTs including mode of action and recent comparative trials, on targeted immunotherapies defined by specific receptors or CD antigens, and on diverse immunosuppressive and cytotoxic drugs. Each lecturer will have 30 minutes including time for discussion to focus on the clinically most relevant targets and mode of actions, identified out of a plethora of possible mechanisms. Importantly also safety aspects will be addressed. Thus we will provide a comprehensive understanding of current and putative future immunotherapeutic approaches applied to different subtypes of MS.

10.30 – 12.00  Teaching Course 9
New technologies in neuroimmunology
Chairs: R. Liblau (Toulouse, FR)
F. Sellebjerg (Copenhagen, DK)

Research in the pathogenesis of inflammatory demyelinating disease is developing rapidly due to the continuous development of novel technologies. The results obtained in animal models have resulted in the development of several MS therapies. This teaching course will cover the use of the animal model experimental autoimmune encephalomyelitis in MS research, and will address how in vivo imaging techniques give new insights into how effector cells enter the central nervous system and how they cause tissue damage. The course will also address how translational research using novel techniques for the study of immunological biomarkers is providing new insights into the pathogenesis and treatment of MS.

10.30 – 12.00  Teaching Course 10
Advanced MR techniques
Chairs: F. Barkhof (Amsterdam, NL)
M. Rocca (Milan, IT)

Advanced MRI techniques offer the possibility to study the pathology of MS in a quantitative fashion, going beyond the qualitative analysis used in a clinical setting. The faculty of MAGNIMS and North-American experts will discuss the benefits and limitations of various quantitative MR techniques that can be used to study damage in lesion and normal appearing white and gray matter. We will also present possibilities to study brain metabolism and activation to understand disability and compensation. Upon completion, the participants should be able to understand the possibilities and limitations of advanced MR techniques, and be able to select the most appropriate technique for their specific research questions.
10.30 – 12.00 Teaching Course 11
Neuroinflammation and tissue repair – what can we learn from animal models?
Chairs: J. Antel (Montreal, CA)
C. Lubetzki (Paris, FR)
Remyelination has been documented to occur in the central nervous system (CNS) in MS by histological and magnetic resonance based imaging criteria. Animal models using toxins to induce CNS demyelination indicate that oligodendrocyte progenitor cells (OPCs) can mediate robust subsequent remyelination. The purpose of this course is to present information regarding i) what the in vitro and in vivo animal models have taught us about the molecular mechanisms regulating remyelination ii) how we can use these models to understand the potential of human OPCs to carry out remyelination iii) how we can identify new mediators, receptors, or signaling pathways that if enhanced or inhibited would promote the remyelination process and iv) how we can relate imaging modalities to specific repair responses leading to translation of the basic studies into the clinic.

10.30 – 12.00 Teaching Course 12
From genes to function
Chairs: L. Fugger (Oxford, UK)
T. Olsson (Stockholm, SE)
The genetics of MS has since long had its own agenda focused on finding genes associated to disease, because such genes would denote central pathogenic mechanisms, which in turn would be attractive as therapeutic targets and perhaps provide more selective therapeutic strategies than we have today. However, most efforts have been spent on finding the genes, but so far not to understand their function. In this teaching course efforts to understand the function of MS risk genes are discussed, both for the major MS risk genes in the HLA complex, and selected non-HLA genes.

12.00 – 12.30 Lunch Break

12.30 – 14.00 Satellite Symposium
European Charcot Foundation

14.00 – 15.30 Young Scientific Investigators’ Session I
Chairs: H. Vrenken (Amsterdam, NL)
G. Edan (Rennes, FR)

15.30 – 16.00 Coffee Break

16.00 – 17.15 Young Scientific Investigators’ Session II
Chairs: B. van Oosten (Amsterdam, NL)
J. Lycke (Gothenburg, SE)

17.15 – 18.15 Satellite Symposium
The oral therapy revolution in MS: clinical experience and future in patient care
Sanofi-aventis

20.00 Welcome Reception at the National Maritime Museum Amsterdam
(see page 22 for further details)

Call for proposal of future teaching courses
The ECTRIMS Executive Committee encourages everyone with interest in multiple sclerosis to send proposals for future teaching courses to the ECTRIMS Administrative Secretariat. Your proposal should contain a title of the teaching course, two organizers and three or four lecturers (including the 2 organizers) as well as the titles of the lecturers. The deadline for handing in 2012 teaching course proposals is on 1 December 2011. Please send your proposal to:

ECTRIMS Administrative Secretariat
c/o Congrex Switzerland Ltd.
Peter Merian-Strasse 80
4002 Basel / Switzerland
E-mail olivia.montanari@congrex.com
Scientific Programme

Plenary Session

08.30 – 10.00 Plenary Session 1
Welcome address and ECTRIMS Lecture
Chairs: C. Polman (Amsterdam, NL)
M. Clanet (Toulouse, FR)
J. Wolinsky (Houston, US)
Welcome address
C. Polman (Amsterdam, NL)
Welcome to Amsterdam
to be confirmed
ECTRIMS Lecture: Clinical trials in MS – achievements, current and future challenges
L. Kappos (Basel, CH)

10.00 – 10.30 Coffee Break & Poster Viewing

Parallel Sessions

10.30 – 12.00 Parallel Session 1
How to decide whether a patient responds to treatment
Chairs: H. McFarland (Bethesda, US)
H. Wiendl (Münster, DE)
Detecting therapeutic response using early clinical signs and MRI
M. Tintoré (Barcelona, ES)
Detecting therapeutic response using body fluid markers
J. Hillert (Stockholm, SE)
Platform presentation of related original papers

10.30 – 12.00 Parallel Session 2
Cellular infiltration into the brain: new ways for immunomodulation in MS
Chairs: T. Derflus (Basel, CH)
H. de Vries (Amsterdam, NL)
Blood-brain-barrier, chemokines and MS
A. Prat (Montreal, CA)
Molecular imaging and cellular labelling
V. Dousset (Bordeaux, FR)
Platform presentation of related original papers

10.30 – 12.00 Parallel Session 3
OCT in MS
Chairs: A. Green (San Francisco, US)
A. Petzold (Amsterdam, NL)
OCT of the retina: applications in neurology
G. Plant (London, UK)
OCT in optic neuritis and MS subtypes
L. Balcer (Philadelphia, US)
Platform presentation of related original papers

12.00 – 12.45 Lunch Break & Poster Viewing

Satellite Symposium

12.45 – 13.45 Satellite Symposium Biogen Idec

Parallel Sessions

14.00 – 15.30 Parallel Session 4
Functional reorganisation and rehabilitation
Chairs: J. Kesselring (Valens, CH)
F. Barkhof (Amsterdam, NL)
CNS plasticity in non-MS neurodegenerative disease
L. Calza (Bologna, IT)
CNS plasticity in MS
P. Matthews (Oxford, UK)
Platform presentation of related original papers

14.00 – 15.30 Parallel Session 5
New biomarkers for MS
Chairs: B. Hemmer (Munich, DE)
C. Teunissen (Amsterdam, NL)
Use of genomic discoveries for clinical practice
S. Baranzini (San Francisco, US)
Identification and clinical evaluation of novel CSF biomarkers
M. Comabella (Barcelona, ES)
Platform presentation of related original papers

14.00 – 15.30 Parallel Session 6
Paediatric MS
Chairs: B. Banwell (Toronto, CA)
R. Hintzen (Rotterdam, NL)
What can paediatric MS teach us about adult onset MS?
E. Waubant (San Francisco, US)
Special practical and ethical challenges related to therapies and clinical trials in paediatric MS
S. Tenembaum (Buenos Aires, AR)
Platform presentation of related original papers

Poster Session

15.30 – 17.00 Poster Viewing Session
# Scientific Programme

**Thursday, 20 October 2011**

## Hot Topics in MS

### 17.00 – 17.45 Hot Topic 1

**Diagnostic criteria for MS**  
**Chairs:** X. Montalban (Barcelona, ES)  
F. Fazekas (Graz, AT)

- The 2010 Dublin revisions to the McDonald diagnostic criteria  
  C. Polman (Amsterdam, NL)
- Shifting phenotype and ‘NMO-spectrum disorders’  
  S. Vukusic (Lyon, FR)
- Platform presentation of related original papers

### 17.00 – 17.45 Hot Topic 2

**Mitochondria in MS**  
**Chairs:** H.-P. Hartung (Düsseldorf, DE)  
H. Lassmann (Vienna, AT)

- Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration  
  J. van Horssen (Amsterdam, NL)
- Mitochondrial metabolism and repair in MS  
  O. Ciccarelli (London, UK)
- Platform presentation of related original papers

### 17.00 – 17.45 Hot Topic 3

**High field MRI in MS**  
**Chairs:** M. Filippi (Milan, IT)  
D. Pelletier (Yale, US)

- High-field imaging and improved cortical visualization  
  K. Schmierer (London, UK)
- High field is high yield? Impact on diagnosis  
  M. Wattjes (Amsterdam, NL)
- Platform presentation of related original papers

## Satellite Symposia

- **18.00 – 19.00** Satellite Symposium Merck Serono S.A.
- **19.15 – 20.15** Satellite Symposium Bayer Schering Pharma AG
Scientific Programme

07.30 – 09.00  ECTRIMS Council Meeting
Council members, by invitation only

Satellite Symposium
08.00 – 09.00  Satellite Symposium
Multimodal management in MS – improving quality of life
Allergan

Parallel Sessions
09.15 – 10.15  Platform presentation of selected abstracts I
Chairs: G. Giovannoni (London, UK)
M. Clanet (Toulouse, FR)

Platform presentation of selected abstracts II
Chairs: F. Zipp (Berlin, DE)
J. Correale (Buenos Aires, AR)

Platform presentation of selected abstracts III
Chairs: P. O’Connor (Toronto, CA)
N. Scolding (Bristol, UK)

10.15 – 10.45  Coffee Break & Poster Viewing

10.45 – 12.15 Parallel Session 7
Grey matter damage in MS
Chairs: B. Trapp (Cleveland, US)
P. van der Valk (Amsterdam, NL)
Visualization and mechanisms of grey matter damage
J. Geurts (Amsterdam, NL)
Clinical consequences of grey matter damage
R. Rudick (Cleveland, US)

Platform presentation of related original papers

10.45 – 12.15 Parallel Session 8
The importance of B-cells in MS
Chairs: P. Soelberg Sorensen (Copenhagen, DK)
C. Dijkstra (Amsterdam, NL)
CNS B-cells: do they matter?
F. Aloisi (Rome, IT)
Effects of peripheral B-cell depletion
A. Bar-Or (Montreal, CA)

Platform presentation of related original papers

10.45 – 12.15 Parallel Session 9
How to measure clinical progression
Chairs: A. Thompson (London, UK)
B. Uitdehaag (Amsterdam, NL)
Demonstrating surrogacy for measures of clinical progression
M. Sormani (Genoa, IT)
Novel ways to measure disease progression
J. Cohen (Cleveland, US)

Platform presentation of related original papers

12.15 – 12.45  Lunch Break & Poster Viewing

Satellite Symposium
12.45 – 13.45 Satellite Symposium
Fingolimod treatment experience: efficacy and safety in clinical practice
Novartis Pharma AG

Parallel Sessions
14.00 – 15.30 Parallel Session 10
Cognitive decline in MS
Chairs: R. Benedict (Buffalo, US)
M. Amato (Florence, IT)
Effects of memory training
N. Chiaravalloti (Newark, US)
Pharmacological approaches to memory decline
D. Bourdette (Portland, US)

Platform presentation of related original papers

14.00 – 15.30 Parallel Session 11
Cell based therapy in MS
Chairs: M. Freedman (Ottawa, CA)
E. Boddeke (Groningen, NL)
Promoting differentiation of oligodendrocyte precursor cells and remyelination
H. Keirstead (Irvine, US)
Cell-based remyelinating therapies in MS: evidence from experimental studies
G. Martino (Milan, IT)

Platform presentation of related original papers

14.00 – 15.30 Parallel Session 12
New developments in the epidemiology of MS
Chairs: H. Tremlett (Vancouver, CA)
M. Hutchinson (Dublin, IE)
Effects of comorbidities on MS outcomes
R. Marrie (Winnipeg, CA)
Environmental risk factors as triggers and co-factors for MS
K. Munger (Boston, US)

Platform presentation of related original papers

Poster Session
15.30 – 17.00  Poster Viewing Session

Friday, 21 October 2011
Scientific Programme

Hot Topics in MS

17.00 – 17.45
Hot Topic 4
CCSVI
Chairs: G. Comi (Milan, IT)
O. Khan (Detroit, US)
Review of current data related to CCSVI
and MS
F. Doepp (Berlin, DE)
New media and communication with patients:
CCSVI as a case-study
A. Miller (New York, US)
Platform presentation of related original papers

17.00 – 17.45
Hot Topic 5
MS: neurodegeneration
Chairs: W. Brück (Göttingen, DE)
C. Lubetzki (Paris, FR)
Pathological substrates of MS neurodegeneration
C. Stadelmann (Göttingen, DE)
Contribution of systemic inflammation to MS
neurodegeneration
V. Perry (Southampton, UK)
Platform presentation of related original papers

17.00 – 17.45
Hot Topic 6
Risk management for disease-modifying
treatments in MS
Chairs: F. Lublin (New York, US)
J. Killestein (Amsterdam, NL)
Trajectory of development of risk management:
needs and strategies
J. Wolinsky (Houston, US)
How post-marketing registries contribute
to patient safety
M. Trojano (Bari, IT)
Platform presentation of related original papers

Satellite Symposia

18.00 – 19.00
Satellite Symposium
Moving forward in MS spasticity symptoms
management
Almirall

19.15 – 20.15
Satellite Symposium
Alemtuzumab MS symposium
Genzyme

Social event

Official Conference Dinner at the Beurs van
Berlage (see page 23 for further details)
Parallel Sessions

08.30 – 09.30 Parallel Session 13
**Late breaking news**
Chairs: R. Hohlfeld (Munich, DE)
P. Calabresi (Baltimore, US)

09.30 – 10.15 Charcot Lecture
Chairs: A. Thompson (London, UK)
C. Polman (Amsterdam, NL)
Mechanistic biomarkers to guide therapy for multiple sclerosis
L. Steinman (Stanford, US)

10.15 – 10.45 Coffee Break & Poster Viewing

10.45 – 11.30 ACTRIMS Donald Paty Memorial Lecture
Chairs: J. Wolinsky (Houston, US)
M. Clanet (Toulouse, FR)
The role of the innate immune system in the progressive phase of MS
H. Weiner (Boston, US)

Plenary Session

11.30 – 13.00 Plenary Session 2
**ECTRIMS / ACTRIMS highlights**
Chairs: J. Wolinsky (Houston, US)
M. Clanet (Toulouse, FR)

ECTRIMS / ACTRIMS 2011 highlights: trials
R. Gold (Bochum, DE)

ECTRIMS / ACTRIMS 2011: scientific highlights
J. Antel (Montreal, CA)

Presentation of selected poster awards, awards for best oral presentations by young researchers and the MSIF award
M. Clanet (Toulouse, FR); M. Trojano (Bari, IT)

Welcome to Lyon 2012
C. Confavreux (Lyon, FR)

End of meeting
Call for Abstracts

The Scientific Committee welcomes the submission of abstracts for presentation at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis.

Deadline for submission of abstracts: Thursday, 26 May 2011

Abstracts may only be submitted online. To submit your abstract please go to the congress website www.ectrims.eu/2011

In order to standardise the abstract layout, we kindly ask you to read the guidelines at this link carefully.

Guidelines for preparation of abstracts
1. Abstracts may only be submitted online. Abstracts submitted by fax or email will not be accepted.
2. Abstracts must be submitted in English. Please use UK English spelling.
3. The presenting author of an accepted abstract must register and attend the congress.
4. Poster presenters must be present and stand by their posters during their assigned poster sessions.
5. Abstracts should contain only original material not published or presented elsewhere prior to 19 October 2011.
6. Use a short specific title indicating the nature of the investigation. The background and goals of the study should appear clearly to the reader. The methods and results must contain data, and the conclusions should be clearly expressed.
7. All abbreviations must be defined the first time they appear in your text (but, do not define in the title). Example: Multiple Sclerosis Impact Scale (MSIS), before being used as an abbreviation only.
8. Avoid complex mathematical formulae. For the symbols ≤ or ≥, type instead <= or >=. For superscript use caret (^) e.g. 10^6 instead of 10^6. Do not use Greek letters and symbols. Instead of “IFN-γ” use for example “IFN-g” or “IFN-gamma”.
9. Use generic drug names.
10. Tables, charts or other graphics may not be included and will be deleted by the editors.
11. The abstract text may not be longer than 2500 characters including spaces (ca. 500 words).
12. Authors should indicate their presentation preference:
   • poster presentation only
   • oral or poster presentation
   “Poster only” implies that your abstract will be considered for poster presentation only and will not be eligible for the poster prize (see corresponding paragraph).
   The Programme Committee reserves the right to decide on the final allocation and presentation method.
13. A selected number of abstracts will be accepted for oral presentation based on their scientific merits and on their relation to the topics addressed in the scientific programme of the Congress. We therefore encourage submissions on the main topics covered in the scientific programme.
14. Disclosure of conflict of interest (e.g. grant support, consultancy, membership on advisory councils, speaker’s bureau) and source of funding is mandatory. Each listed author should prepare a one sentence statement to this effect.
15. Please make sure to state your correct e-mail address. After having submitted your abstract, you will receive a confirmation by e-mail with the following information:
   • reference number of your abstract (for correspondence and questions that might arise)
   • your personal user code and password.
   (If you do not receive a confirmation by e-mail please contact the Abstract Hotline!)
16. Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal access codes. This will shorten the submission procedure. Corrections to abstracts can only be made up to the deadline of 26 May 2011.

If you have difficulties in submitting your abstracts or if you need any further information, please contact the Abstract Hotline (Monday – Friday during CET business hours): Tel. +41 61 686 77 22.

The number of representatives on the ECTRIMS Council from each European ECTRIMS member country will be dependent upon the number of accepted abstracts for Congresses.